Romiplostim N01 plus ATRA for low platelets after cancer treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had gynecologic (ovarian, endometrial, cervical), breast, or lung cancer that has completely gone away
- Your cancer treatment ended at least 12 weeks ago and you don't need more cancer-directed therapy right now
- Your platelet count has stayed below 30,000 per microliter of blood (or slightly higher but needing transfusions) since chemotherapy ended
- Your red blood cells and neutrophils (white blood cells) are normal or near-normal
- You've tried at least one other platelet-boosting drug before and it didn't work well enough
- You have no other blood disorders, active cancer, serious infections, or severe heart/liver/kidney problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests a new version of a drug called romiplostim to help raise platelet counts in breast cancer patients whose platelets drop because of chemotherapy. Raising your platelets may reduce the risk of bleeding and allow you to continue your cancer treatment.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests a drug called romiplostim to prevent low platelet counts (a condition that raises bleeding risk) caused by chemotherapy in people with breast cancer. If you qualify, you may receive this drug to help keep your platelets at a safer level during future treatments.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.